8-K: Exicure Reports 2025 Results, Faces Liquidity Challenges

Exicure, Inc. announced its full year 2025 financial results, revealing a significant decrease in cash and a going concern warning despite a reduced net loss driven by a one-time gain.

Summary

• Cash and cash equivalents decreased to $3.7 million as of December 31, 2025, from $12.5 million as of December 31, 2024.
• Research and development expenses increased to $3.3 million for the year ended December 31, 2025, from $0 in 2024, following the acquisition of GPCR Therapeutics USA Inc.
• General and administrative expenses rose to $6.8 million in 2025 from $5.4 million in 2024, primarily due to the GPCR USA acquisition and integration.
• The company recognized a $6.0 million gain from the early termination of its Chicago office lease, effective January 31, 2025.
• Net loss for the year ended December 31, 2025, was $4.9 million, a decrease from $9.7 million in 2024, largely due to the lease termination gain.
• Management believes current liquidity is insufficient to fund operations for the next 12 months and substantial additional financing is required.
• Exicure acquired a clinical-stage biotechnology company, GPCR Therapeutics USA Inc., in January 2025, shifting its focus to developing therapeutics for hematologic diseases.
• The lead program is being evaluated for improving stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative report due to the severe liquidity issues, explicit going concern warning, and immediate need for substantial financing, despite a reduced net loss driven by a one-time gain.

Positives

• Net loss decreased to $4.9 million in 2025 from $9.7 million in 2024.
• Recognized a $6.0 million gain from the early termination of the Chicago office lease.
• Acquisition of GPCR Therapeutics USA Inc. in January 2025 provides a new clinical-stage lead program focused on hematologic diseases.
• Recognized a $346,000 gain in the third quarter of 2025 upon satisfying its self-insured retention with its insurer.

Negatives

• Cash and cash equivalents significantly declined to $3.7 million as of December 31, 2025, from $12.5 million as of December 31, 2024.
• Current liquidity is believed to be insufficient to fund operations for the next 12 months.
• Increased R&D expenses to $3.3 million in 2025 from $0 in 2024.
• Increased G&A expenses to $6.8 million in 2025 from $5.4 million in 2024.
• Recognized a $90,000 loss from the sale or disposal of property and equipment by GPCR USA.
• Recorded a $1,553,000 loss related to the change in fair value of its contingent liability.
• Recognized a $275,000 loss associated with the sale of its subsidiary, KC Creation, along with additional currency translation losses.
• The decrease in net loss was primarily driven by a one-time gain from lease termination, masking underlying operational cash burn.

Risks

• Existing cash and cash equivalents are not sufficient to fund operations for the next 12 months.
• Substantial additional financing is needed in the short term to pay expenses and fund ongoing operations and strategic alternatives.
• There is no assurance that additional financing will be available or obtainable on acceptable terms.
• The company's ability to further cut costs and extend its operating runway is limited.
• Forward-looking statements are subject to risks and uncertainties and are not guarantees of future performance.

Future Outlook

Exicure is actively exploring strategic alternatives to maximize stockholder value and needs substantial additional financing in the short term to fund operations and pursue identified alternatives. The company's ability to further cut costs and extend its operating runway is limited, and there is no assurance that required financing will be available on acceptable terms. The company's lead program, acquired in January 2025, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.

Management Comments

• Management believes that the Company's existing cash and cash equivalents is not sufficient to continue to fund operations.
• The Company has already engaged in significant cost reductions, and its ability to further cut costs and extend the Company's operating runway is limited.
• Substantial additional financing is needed in the short term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified.
• The Company also needs to raise capital to fund its operations.

Industry Context

StockSavvy.ai notes that Exicure's pivot from its historical nucleic acid therapy focus to a new clinical-stage program in hematologic diseases, following a restructuring and acquisition, reflects a common strategy for early-stage biotech companies facing pipeline challenges. The significant cash burn and explicit 'going concern' warning, however, highlight the intense capital requirements and inherent risks in drug development, particularly for companies without a clear path to profitability or sufficient funding. The exploration of strategic alternatives is typical for companies in this precarious financial position, seeking to either find a partner, sell assets, or secure new investment to continue operations in a highly competitive and capital-intensive industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Exicure's performance against global industry benchmarks.
• StockSavvy.ai observes that a cash position of $3.7 million with an explicit 'going concern' warning is significantly below the typical liquidity levels considered healthy for a clinical-stage biotechnology company, which often require tens to hundreds of millions of dollars to advance programs through trials.
• The increase in R&D expenses from $0 to $3.3 million following an acquisition is expected for a company restarting development activities, but the overall financial health indicates a critical need for capital that is not uncommon for small, early-stage biotechs, though the severity here is notable.

Stakeholder Impact

• Shareholders: Significant dilution risk if new capital is raised, potential for further share price decline due to going concern warning and liquidity issues. Uncertainty regarding the outcome of strategic alternatives.
• Employees: Potential for further cost reductions or restructuring, leading to job insecurity.
• Creditors: Increased risk of default given the liquidity challenges and going concern warning.
• Customers/Partners: Potential impact on ongoing or future collaborations if financial stability is not secured.

Next Steps

• Secure substantial additional financing in the short term.
• Continue the exploration of strategic alternatives to maximize stockholder value.
• Pursue any strategic alternatives that may be identified.
• Advance the lead program for improving stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.
• Address the Nasdaq Hearings Panel process (mentioned in forward-looking statements, implying it's an ongoing or potential future event).

Key Dates

Recommendation

The explicit 'going concern' warning, critically low cash position of $3.7 million, and immediate need for substantial additional financing with no assurance of availability or acceptable terms present an extremely high risk profile. While the net loss decreased, this was due to a non-recurring gain, masking underlying operational challenges and cash burn. The company's future is highly uncertain without successful capital raising, making it a strong sell for investors seeking to avoid significant capital loss.

Keywords

Exicure, XCUR, Financial Results, 2025, Biotechnology, Liquidity, Going Concern, GPCR Therapeutics, Strategic Alternatives, Cash Position, R&D Expense, Net Loss, Hematologic Diseases, Stem Cell Mobilization, Multiple Myeloma, Sickle Cell Disease, Cell and Gene Therapy